Cardiff University at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Cardiff University brings 3 presentations to ESGCT 2026 in Hamburg. Its work pairs adenoviral cancer therapies with gene therapy for neurodegeneration. The cancer strand arms precision adenoviruses against glioblastoma and modifies the hexon coat to get past neutralising anti-vector immunity, alongside work on treating Huntington's disease.

OrganizationESGCT 2026 Attendance
cardiff.ac.uk
Universities & institutes
Welsh research university with work on Huntington's disease and gene therapies for neurodegeneration.
Poster
Wed Oct 28
1:30pm–3:30pm
Targeting glioblastoma with 'armed' precision adenoviral therapies
Oncolytic therapy & cancer gene therapy
Poster
Thu Oct 29
2:00pm–4:00pm
Generating hexon modified adenoviruses designed to circumvent neutralising anti-vector immunity
Oncolytic therapy & cancer gene therapy
Talk
Fri Oct 30
11:00am–1:00pm
Using gene therapies in Huntington’s disease
SESSION 12a: AAVs/non integrative vectors III - Translation
Rare and inherited diseaseClinical trials and translation

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Cardiff University

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction